Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials

Tyrosine Kinase Inhibitors (TKIs) is revolutionizing the management of pediatric Chronic Myeloid Leukemia (CML), offering alternatives to Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). We conducted a comprehensive review of 16 Randomized Controlled Trials (RCTs) encompassing 887 pediatr...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Fateen Ata, Maria Benkhadra, Rola Ghasoub, Liam J. Fernyhough, Nabil E. Omar, Abdulqadir J. Nashwan, Mahmood B. Aldapt, Kamran Mushtaq, Nancy A. Kassem, Mohamed A. Yassin
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2023-12-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	Tyrosine Kinase Inhibitors TKI pediatric chronic myeloid leukemia CML Imatinib
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1285346/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!